Aptevo Therapeutics Inc. is a clinical-stage biotechnology company that develops novel bispecific and trispecific immunotherapies for cancer treatment. Its product pipeline includes various candidates targeting specific tumor antigens and employing mechanisms such as T cell engagement and costimulation. Aptevo focuses on improving treatment outcomes for patients with hematologic malignancies and solid tumors, operating primarily in the biotechnology sector.
